Ontology highlight
ABSTRACT:
SUBMITTER: Molife LR
PROVIDER: S-EPMC3884022 | biostudies-literature | 2014 Jan
REPOSITORIES: biostudies-literature
Molife L Rhoda LR Yan Li L Vitfell-Rasmussen Joanna J Zernhelt Adriane M AM Sullivan Daniel M DM Cassier Philippe A PA Chen Eric E Biondo Andrea A Tetteh Ernestina E Siu Lillian L LL Patnaik Amita A Papadopoulos Kyriakos P KP de Bono Johann S JS Tolcher Anthony W AW Minton Susan S
Journal of hematology & oncology 20140103
<h4>Background</h4>Inhibition of AKT with MK-2206 has demonstrated synergism with anticancer agents. This phase 1 study assessed the MTD, DLTs, PK, and efficacy of MK-2206 in combination with cytotoxic and targeted therapies.<h4>Methods</h4>Advanced solid tumor patients received oral MK-2206 45 or 60 mg (QOD) with either carboplatin (AUC 6.0) and paclitaxel 200 mg/m2 (arm 1), docetaxel 75 mg/m2 (arm 2), or erlotinib 100 or 150 mg daily (arm 3); alternative schedules of MK-2206 135-200 mg QW or 9 ...[more]